Intech Investment Management LLC Increases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Intech Investment Management LLC raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 219.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,131 shares of the medical equipment provider's stock after buying an additional 33,747 shares during the quarter. Intech Investment Management LLC owned about 0.07% of Lantheus worth $5,392,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC raised its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC increased its stake in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock valued at $1,834,000 after acquiring an additional 100 shares during the last quarter. UMB Bank n.a. raised its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. GAMMA Investing LLC lifted its stake in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after purchasing an additional 146 shares during the last quarter. Finally, Moody National Bank Trust Division boosted its holdings in shares of Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock worth $1,203,000 after purchasing an additional 162 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LNTH. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a report on Thursday. Truist Financial reissued a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Finally, JMP Securities decreased their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Stock Up 3.7 %

Shares of Lantheus stock opened at $90.52 on Friday. The company's fifty day simple moving average is $103.43 and its two-hundred day simple moving average is $96.53. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The firm has a market cap of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.